GlassScriptPhysician profile
Jeffrey D Rettig
NPI 1528005550
$6,349.26
in general payments reported to CMS, 2019-2025
41 companies · $669 in 2025
The $669 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $1,003 · 2021: $1,107 · 2022: $939 · 2023: $704 · 2024: $844 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,035.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $957.15 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $548.76 | 2019-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $395.09 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $299.54 | 2024 | Voquezna |
| Lundbeck LLC | $253.57 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $246.37 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.06 | 2021-2025 | Xifaxan |
| Abbvie INC. | $204.51 | 2021-2025 | |
| Mylan Specialty L.P. | $188.47 | 2020-2022 | |
| Pfizer INC. | $184.73 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.04 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $159.93 | 2019-2023 | |
| Astellas Pharma US INC | $137.37 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $134.71 | 2024-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rettig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.